Basisstatistiken
| LEI | 549300ZC1GPV35XYDK53 |
| CIK | 12208 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bio-Rad Laboratories, Inc.
SEC Filings (Chronological Order)
Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.
| May 13, 2026 |
Bio-Rad Laboratories, Inc. Conflict Minerals Report Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2025 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13p-1 to implement reporting and disclosure requirements relating to con |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 001-07928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal |
|
| April 30, 2026 |
ex992-bioxrad1q26earning Supplemental Earnings Results Presentation April 30, 2026 First Quarter 2026 Financial Results 2 Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management’s goals, plans, and expectations, our future financial performance, our future financial projections, our growth strategy, and other matters. |
|
| April 30, 2026 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A Common Stock |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-07928 BIO-RAD LA |
|
| April 30, 2026 |
Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2026 Financial Results HERCULES, Calif.—April 30, 2026 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2026. Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: "Our firs |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 30, 2026 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction of |
|
| April 30, 2026 |
As filed with the Securities and Exchange Commission on April 30, 2026 As filed with the Securities and Exchange Commission on April 30, 2026 Registration No. |
|
| April 24, 2026 |
AMENDED BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN (as amended March 18, 2026) ARTICLE 1. Exhibit 10.1 AMENDED BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN (as amended March 18, 2026) ARTICLE 1. PURPOSE The purpose of the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan (as amended on February 9, 2024 and as further amended on March 18, 2026, as so amended, the “Plan”) is to promote the success and enhance the value of Bio-Rad Laboratories, Inc. (the “Company”) by linking t |
|
| April 24, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 21, 2026 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction of in |
|
| March 25, 2026 |
We advance science and save lives, together. 2025 ANNUAL REPORT21% Reference labs Bio-Rad is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7 ,400 employees a |
|
| March 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ☑ Filed by the Registrant ☐ Filed by a party other than the Registrant CHECK THE APPROPRIATE BOX: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☑ Defin |
|
| March 25, 2026 |
BIO -RAD Bio-Rad Laboratories, Inc. 1000 Alfred Nobel Drive Hercules, California 94547 Notice of Annual Meeting of Stockholders Tuesday, April 21 2026 4:00 p.rn. Pacific Daylight Time 1000 Alfred Nobel Drive, Hercules, California 94547 ) TO THE STOCKHOLDERS OF BIO-RAD LABORATORIES, INC.: The annual meeting of the stockholders of Bio-Rad Laboratories, Inc. will be held at our corporate offices, 100 |
|
| February 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 19, 2026 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 13, 2026 |
Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium Bio-Rad Laboratórios Brasil Ltda. Brazil Bio-Rad Laboratories (Canada) Limited Canada Bio-Rad Laboratories (Shanghai) Co., Ltd. China Bio-Rad (Shanghai) Life Scien |
|
| February 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORI |
|
| February 12, 2026 |
bio-radq4andfy25earnings Supplemental Earnings Results Presentation February 12, 2026 Fourth-Quarter and Full-Year 2025 Results 2 Safe Harbor Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management’s goals, plans, and expectations, our future financial performance, our future financial projections, our growth strategy, and other matters. |
|
| February 12, 2026 |
Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results HERCULES, Calif.—February 12, 2026 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full-year ended December 31, 2025. Norman Schwartz, Bio-Rad’s Chief Executive Off |
|
| February 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 12, 2026 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-07928 BIO-RA |
|
| October 29, 2025 |
Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2025 Financial Results HERCULES, Calif.—October 29, 2025 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2025. “During the third quarter, we continued to navigate a dynamic global environ |
|
| October 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 29, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction of |
|
| October 29, 2025 |
a3q25supplementalearning October 29, 2025 Third Quarter 2025 Financial Results Bio-Rad Laboratories, Inc. |
|
| September 30, 2025 |
Exhibit 99.1 Press Release Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away HERCULES, Calif.— September 29, 2025 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Alice N. Schwartz, Bio-Rad’s co-founder and Director Emeritus, passed away on September 25, 2025, at |
|
| September 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 29, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction o |
|
| August 26, 2025 |
dropletdigitalpcrpresent Bio-Rad Laboratories, Inc. NYSE: BIO and BIO.B August 26, 2025 Droplet Digital PCR – Powering the Future Safe Harbor Forward-Looking Statements. Some statements in this presentation and the related webinar and Q&A session may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements r |
|
| August 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 26, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-07928 BIO-RAD LAB |
|
| July 31, 2025 |
Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2025 Financial Results HERCULES, Calif.—July 31, 2025 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2025. Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “In a hig |
|
| July 31, 2025 |
supplementalearningspres 1 July 31, 2025 Second Quarter 2025 Financial Results Bio-Rad Laboratories, Inc. |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 31, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 28, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| July 28, 2025 |
Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations Exhibit 99.1 Press Release Bio-Rad Appoints Rajat Mehta Executive Vice President, Global Commercial Operations HERCULES, Calif. – July 28, 2025 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the appointment of Rajat Mehta as its new Executive Vice President, Global Commercial Operations, effective Augu |
|
| June 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 30, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco |
|
| May 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELWARE 001-07928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal |
|
| May 20, 2025 |
Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2024 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and disclosure requirements relating to co |
|
| May 1, 2025 |
Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2025 Financial Results HERCULES, Calif.—May 1, 2025 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2025. Norman Schwartz, Bio-Rad’s Chairman and Chief Executive Officer, stated: “We navigate |
|
| May 1, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 1, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| May 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-07928 BIO-RAD LA |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 22, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-07928 Delaware 94-1381833 (State or other jurisdiction of in |
|
| March 26, 2025 |
Bio-Rad Laboratories Annual Report 2024 We advance science and save lives, together. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 21, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORI |
|
| February 14, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 Bio-Rad Laboratories, Inc. Insider Trading Compliance Policy Federal laws and regulations prohibit trading in the securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws and regulations also prohibit anyone who is aware of material nonpublic information from providing this information to others who may tr |
|
| February 14, 2025 |
Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium Bio-Rad Laboratórios Brasil Ltda. Brazil DiaMed Latino América S.A. Brazil Bio-Rad Laboratories (Canada) Limited Canada Bio-Rad Laboratories (Shanghai) Co., Ltd. C |
|
| February 13, 2025 |
Exhibit 99.2 Press Release Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies Transaction To Complement Bio-Rad’s Existing Digital PCR Portfolio and Accelerate Development of Next-Generation Digital PCR Solutions HERCULES, Calif. — [BUSINESS WIRE] - February 13, 2025 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnosti |
|
| February 13, 2025 |
Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 7, 2025 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| February 13, 2025 |
Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2024 Financial Results HERCULES, Calif.—February 13, 2025 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Norman Schwartz, Bio-Rad’s Chairman and Chief |
|
| November 14, 2024 |
BIO / Bio-Rad Laboratories, Inc. / VAN ECK ASSOCIATES CORP Passive Investment SC 13G 1 bio-radlaboratoriesinc13g.htm SC 13G schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIO-RAD LABORATORIES, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 090572207 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| November 12, 2024 |
BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 12)* (Name of Issuer) Bio-Rad Laboratories Inc (Title of Class of Securities) Common Stock (CUSIP Number) |
|
| November 8, 2024 |
BIO / Bio-Rad Laboratories, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us0905722072110824.txt us0905722072110824.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 11) BIO-RAD LABORATORIES INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 090572207 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the |
|
| November 4, 2024 |
BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC Passive Investment 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 11)* (Name of Issuer) Bio-Rad Laboratories Inc (Title of Class of Securities) Common Stock (CUSIP Number) |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-07928 BIO-RAD |
|
| October 31, 2024 |
Exhibit 10.1 BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE (NON-EMPLOYEE DIRECTOR FORM) Bio-Rad Laboratories, Inc., a Delaware corporation, (the “Company”), pursuant to its 2017 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Holder”), Restricted Stock Units (“RSUs”) with respect to the |
|
| October 30, 2024 |
Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2024 Financial Results HERCULES, Calif.—October 30, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 p |
|
| October 30, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 30, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction o |
|
| October 24, 2024 |
OCX / OncoCyte Corporation / BIO-RAD LABORATORIES, INC. - SC 13G/A Passive Investment SC 13G/A 1 formsc13gaoctober2024.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Oncocyte Corporation (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 68235C107 (CUSIP Number) October 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| October 22, 2024 |
BIO / Bio-Rad Laboratories, Inc. / BlackRock, Inc. Passive Investment SC 13G/A 1 us0905722072102224.txt us0905722072102224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 11) BIO-RAD LABORATORIES INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 090572207 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the |
|
| October 10, 2024 |
BIO / Bio-Rad Laboratories, Inc. / BANK OF NOVA SCOTIA - BANK OF NOVA SCOTIA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* BIO-RAD LABORATORIES (Name of Issuer) Common Shares (Title of Class of Securities) 90572207 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sc |
|
| October 10, 2024 |
BIO / Bio-Rad Laboratories, Inc. / BANK OF NOVA SCOTIA - BANK OF NOVA SCOTIA Passive Investment SC 13G 1 bio101024.htm BANK OF NOVA SCOTIA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 BIO-RAD LABORATORIES (Name of Issuer) Common Shares (Title of Class of Securities) 90572207 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| September 9, 2024 |
Amended and Restated Bylaws of Bio-Rad Laboratories, Inc. effective September 6, 2024 (redline) EXHIBIT 3.2 BYLAWS OF BIO-RAD LABORATORIES, INC. (as amended and restated effective October 25, 2017September 6, 2024) OFFICES SECTION 1. Registered Office. The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. SECTION 2. Principal Office. The principal office for the transaction of the business of the corporation is hereby fixed and located at 1000 Alf |
|
| September 9, 2024 |
Amended and Restated Bylaws of Bio-Rad Laboratories, Inc. EXHIBIT 3.1 BYLAWS OF BIO-RAD LABORATORIES, INC. (as amended and restated effective September 6, 2024) OFFICES SECTION 1.Registered Office. The registered office shall be in the City of Wilmington, County of New Castle, State of Delaware. SECTION 2.Principal Office. The principal office for the transaction of the business of the corporation is hereby fixed and located at 1000 Alfred Nobel Drive, H |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 6, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| August 20, 2024 |
Exhibit 99.1 Press Release Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer HERCULES, Calif.— August 20, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Jon DiVincenzo will join the company as President and Chief Operating Officer, effective September 9, 2024, replacing Andy |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 15, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of in |
|
| August 20, 2024 |
. DiVincenzo dated August 2, 2024 Exhibit 10.1 August 2, 2024 Jon DiVincenzo 10157 Hickory Ridge Drive Zionsville, IN 46077 Dear Jon, I am pleased to extend to you our written offer of employment to join Bio-Rad Laboratories as President & Chief Operating Officer, reporting directly to Norman Schwartz. In your new position, your bi-weekly salary is $25,576.92 which is equivalent to $665,000 USD annually. You are eligible to partic |
|
| August 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-07928 BIO-RAD LABO |
|
| August 1, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 29, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| August 1, 2024 |
Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2024 Financial Results HERCULES, Calif.—August 1, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the second quarter ended June 30, 2024. Second-quarter 2024 total net sales were $638.5 million, a decrease of 6.3 percen |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-RAD LABORATORIES, INC. (Exact Name of Registrant as Specified in Charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or Other Jurisdiction of Incorporation) (IRS Employer Identification Number) 1000 Alfred Nobel Dr. Hercules, California 94547 (Address of principal exe |
|
| May 9, 2024 |
Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2023 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and disclosure requirements relating to co |
|
| May 8, 2024 |
As filed with the Securities and Exchange Commission on May 8, 2024 As filed with the Securities and Exchange Commission on May 8, 2024 Registration No. |
|
| May 8, 2024 |
Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Class A Common Stock |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 001-07928 BIO-RAD LAB |
|
| May 7, 2024 |
Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2024 Financial Results HERCULES, Calif.—May 7, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent com |
|
| May 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 7, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| April 26, 2024 |
Exhibit 99.1 Press Release Bio-Rad Announces Life Science Group Management Changes HERCULES, Calif.— April 26, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and Pr |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 22, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 001-07928 Delaware 94-1381833 (State or other jurisdiction of |
|
| April 26, 2024 |
Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan, as amended Exhibit 10.1 BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN (as amended February 9, 2024) ARTICLE 1. PURPOSE The purpose of the Bio-Rad Laboratories, Inc. 2017 Incentive Award Plan (as amended on February 9, 2024, the “Plan”) is to promote the success and enhance the value of Bio-Rad Laboratories, Inc. (the “Company”) by linking the individual interests of the members of the Board and Employ |
|
| April 22, 2024 |
OCX / OncoCyte Corporation / BIO-RAD LABORATORIES, INC. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 Oncocyte Corporation (Name of Issuer) Common Shares, No Par Value (Title of Class of Securities) 68235C107 (CUSIP Number) April 15, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sched |
|
| April 10, 2024 |
Exhibit 99.1 Press Release Bio-Rad's Chief Operating Officer Andrew Last to Retire HERCULES, Calif.— April 10, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will |
|
| April 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 10, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| March 27, 2024 |
We advance science & save lives, together. Bio-Rad Laboratories 2023 ANN UAL RE P ORTDǷɅĭɅƔǷĭȦΈZǷǓǨȦǷǓǨʯʣΈ̈́͂̓͋Ӟ́͂̈́ͅ CASH FLOW FROM OPERATIONS εΈÖ η $ 375 2023 Ϯ Έ̓͋ ͆ ̈́͂̈́̈́ Ϯ Έ͈͈ ͋ ̈́͂̈́̓ Ϯ Έ͇͊ ͇ ̈́͂̈́͂ $Έ͆ ͇͊ ̈́ ͂ ̓͋ OPERATING INCOME εΈÖ η $ 338 2023 ϮΈ ͆͊ ͅ ̈́͂̈́̈́ ϮΈ ͇ ͂ ͂ ̈́͂̈́̓ Ϯ Έ͆ ̈́̓ ̈́͂̈́͂ $Έ̈́ ͅ ͂ ̈́͂̓ ͋ NET REVENUE ε Öη $ 2,671 2023 Ϯ ̈́ Γ͊ ͂ ̈́ ̈́͂̈́̈́ Ϯ Έ̈́ Γ͋̈́ͅ ̈́͂̈́̓ Ϯ ̈́ Γ͇͈͆ ̈́͂̈́͂ $Έ̈́ Γ |
|
| March 20, 2024 |
Employment Offer Letter between the Company and Roop K. Lakkaraju dated February 14, 2024 Exhibit 10.1 February 14, 2024 Roop Lakkaraju 1121 Grimley Lane San Jose, CA 95120 Dear Roop, I am pleased to extend to you our written offer of employment to join Bio-Rad Laboratories as Executive Vice President, Chief Financial Officer, reporting directly to Norman Schwartz. In your new position, your bi-weekly salary is $23,076.92, which is equivalent to USD $600,000 annually. You are eligible |
|
| March 20, 2024 |
Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer Exhibit 99.1 Press Release Bio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial Officer HERCULES, Calif.— March 20, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, e |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 20, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| March 11, 2024 |
BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Bio-Rad Laboratories, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: February 29, 2024 Check the appropriate box to designate the rule pursuant to which this Sche |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 21, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 16, 2024 |
Policy for Recovery of Erroneously Awarded Compensation, effective as of October 2, 2023 BIO-RAD LABORATORIES, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Bio-Rad Laboratories, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined in the text of this Policy are defined in Section 11. 1.Persons S |
|
| February 16, 2024 |
Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium Bio-Rad Laboratórios Brasil Ltda. Brazil DiaMed Latino-América S.A. Brazil Bio-Rad Laboratories (Canada) Limited Canada Bio-Rad Laboratories (Shanghai) Co., Ltd. C |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORI |
|
| February 15, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 15, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 15, 2024 |
Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial Results HERCULES, Calif.—February 15, 2024 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth-quarter 2023 total net sales were $681. |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 9, 2024 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| February 14, 2024 |
EXHIBIT 10.1 CREDIT AGREEMENT dated as of February 13, 2024 among BIO-RAD LABORATORIES, INC., BIO-RAD EUROPE GMBH, BIO-RAD IHC EUROPE GMBH, AND BIO-RAD LABORATORIES (SINGAPORE) PTE LTD, as Borrowers, THE LENDERS, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Agent WELLS FARGO SECURITIES, LLC, JPMORGAN CHASE BANK, N.A., and CITIBANK, N.A., as Joint Lead Arrangers and Joint Bookrunners and JPMORGAN |
|
| February 13, 2024 |
BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0439-bioradlaboratoriesinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Bio-Rad Laboratories, Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropr |
|
| January 29, 2024 |
BIO / Bio-Rad Laboratories, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us0905722072012924.txt us0905722072012924.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 10) BIO-RAD LABORATORIES INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 090572207 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 4, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 26, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| October 26, 2023 |
Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2023 Financial Results HERCULES, Calif.—October 26, 2023 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2023. Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 perc |
|
| October 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 12, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| August 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 21, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of in |
|
| August 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORAT |
|
| August 4, 2023 |
EXECUTION VERSION EXHIBIT 10.1 AMENDMENT NO. 4 Dated as of May 12, 2023 to CREDIT AGREEMENT Dated as of April 15, 2019 THIS AMENDMENT NO. 4 (this “Amendment”) is made as of May 12, 2023 by JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent’), under that certain Credit Agreement, dated as of April 15, 2019, by and among Bio-Rad Laboratories, Inc. (the “Borrower”), the Len |
|
| August 3, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 3, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| August 3, 2023 |
Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2023 Financial Results HERCULES, Calif.—August 3, 2023 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023. Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compar |
|
| July 20, 2023 |
Bio-Rad Announces New Share Repurchase Program Exhibit 99.1 Press Release Bio-Rad Announces New Share Repurchase Program HERCULES, Calif. — July 20, 2023 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding s |
|
| July 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 20, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco |
|
| June 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: June 5, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incor |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) 1000 Alfred Nobel Dr. Hercules, California 94547 (Address of principal ex |
|
| May 24, 2023 |
Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD EX-1.01 2 ex101.htm EX-1.01 Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2022 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and disclosure |
|
| May 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORA |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 4, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incorp |
|
| May 4, 2023 |
Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2023 Financial Results HERCULES, Calif.- May 4, 2023 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023. First-quarter 2023 net sales were $676.8 million, a decrease of 3.3 percent compared t |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 25, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| March 29, 2023 |
Bio-Rad Laboratories Annual Report 2022 Bio-Rad Laboratories 2022 ANNUAL REPORTLETTER TO STOCKHOLDERS This past year marked the 70th anniversary for Bio-Rad. |
|
| March 29, 2023 |
Notice of Annual Meeting of Stockholders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 23, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORIES, INC |
|
| February 17, 2023 |
Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium Bio-Rad Laboratórios Brasil Ltda. Brazil DiaMed Latino-América S.A. Brazil Bio-Rad Laboratories (Canada) Limited Canada Bio-Rad Laboratories (Shanghai) Co., Ltd. C |
|
| February 17, 2023 |
Exhibit 10.1.3 Execution Version AMENDMENT NO. 3 Dated as of February 1, 2023 to CREDIT AGREEMENT Dated as of April 15, 2019 THIS AMENDMENT NO. 3 (this “Amendment”) is made as of February 1, 2023 by and among Bio-Rad Laboratories, Inc. (the “Borrower”), and JPMorgan Chase Bank, N.A., as Administrative Agent (the “Administrative Agent’), under that certain Credit Agreement, dated as of April 15, 20 |
|
| February 16, 2023 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 16, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 16, 2023 |
Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results HERCULES, Calif.—February 16, 2023 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022. Fourth-quarter 2022 net sales were $730.3 millio |
|
| February 9, 2023 |
BIO / Bio-Rad Laboratories, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.2 BIO-RAD LABORATORIES INC CLASS A COMMON STOCK Cusip #090572207 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #090572207 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 234,015 Item 6: 0 Item 7: 235,684 Item 8: |
|
| February 9, 2023 |
BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Bio-Rad Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 1, 2023 |
BIO / Bio-Rad Laboratories, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us0905722072013123.txt us0905722072013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) BIO-RAD LABORATORIES INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 090572207 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the a |
|
| January 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: January 10, 2023 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| January 10, 2023 |
Presentation of Bio-Rad Laboratories, Inc. dated January 10, |
|
| December 16, 2022 |
United States securities and exchange commission logo December 16, 2022 Ajit Ramalingam Senior Vice President, Chief Accounting Officer Bio-Rad Laboratories, Inc. |
|
| December 14, 2022 |
CORRESP 1 filename1.htm December 14, 2022 Michael Fay and Brian Cascio Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Subject: Bio-Rad Laboratories, Inc. Form 10-K for the Year Ended December 31, 2021 SEC Letters Dated April 27, 2022, and December 2, 2022 File No. 001-07928 Dear Messrs. Fay and Cascio: Bio-Rad L |
|
| December 2, 2022 |
United States securities and exchange commission logo December 2, 2022 Ajit Ramalingam Senior Vice President, Chief Accounting Officer Bio-Rad Laboratories, Inc. |
|
| November 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 8, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| October 28, 2022 |
Performance Stock Unit Award Agreement under 2017 Incentive Award Plan. (2 Exhibit 10.1 BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN PERFORMANCE STOCK UNIT AWARD AGREEMENT Pursuant to the Performance Stock Unit Award Grant Notice (the “Grant Notice”) to which this Performance Stock Unit Award Agreement (this “Agreement”) is attached, Bio-Rad Laboratories, Inc., a Delaware corporation (the “Company”), has granted to Holder the right to receive the number of Perfor |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA |
|
| October 27, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 27, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| October 27, 2022 |
Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2022 Financial Results HERCULES, Calif.?October 27, 2022 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2022. Third-quarter 2022 net sales were $680.8 million, a decrease of 8.9 percent co |
|
| August 11, 2022 |
CORRESP 1 filename1.htm August 11, 2022 Michael Fay Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Subject: Bio-Rad Laboratories, Inc. Form 10-K for the Year Ended December 31, 2021 SEC Letter Dated July 29, 2022 File No. 001-07928 Dear Mr. Fay: Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) hereby subm |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORAT |
|
| July 29, 2022 |
United States securities and exchange commission logo July 29, 2022 Ajit Ramalingam Senior Vice President, Chief Accounting Officer Bio-Rad Laboratories, Inc. |
|
| July 28, 2022 |
Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2022 Financial Results HERCULES, Calif.- July 28, 2022 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2022. Second-quarter 2022 net sales were $691.1 million, a decrease of 3.5 percent compar |
|
| July 28, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 28, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco |
|
| May 25, 2022 |
Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. EX-1.01 2 d350596dex101.htm EX-1.01 Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2021 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and di |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 1-7928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal Ex |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 18, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incor |
|
| May 11, 2022 |
CORRESP 1 filename1.htm May 11, 2022 Michael Fay and Brian Cascio Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Subject: Bio-Rad Laboratories, Inc. Form 10-K for the Year Ended December 31, 2021 Filed February 11, 2022 File No. 001-07928 Dear Messrs. Fay and Cascio: Bio-Rad Laboratories, Inc. (“Bio-Rad” or the |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORA |
|
| April 28, 2022 |
Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2022 Financial Results HERCULES, Calif.?April 28, 2022?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2022. First-quarter 2022 net sales were $700.1 million, a decrease of 3.7 percent compared t |
|
| April 28, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 28, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| April 27, 2022 |
United States securities and exchange commission logo April 27, 2022 Ajit Ramalingam Senior Vice President, Chief Accounting Officer Bio-Rad Laboratories, Inc. |
|
| April 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 15, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| April 20, 2022 |
Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 2 Dated as of April 15, 2022 to CREDIT AGREEMENT Dated as of April 15, 2019 THIS AMENDMENT NO. 2 (this ?Amendment?) is made as of April 15, 2022 by and among Bio-Rad Laboratories, Inc. (the ?Borrower?), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the ?Administrative Agent?), under |
|
| April 11, 2022 |
BIO.B / Bio-Rad Laboratories, Inc. / Schwartz Alice N - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8) Bio-Rad Laboratories, Inc. (Name of Issuer) Class B Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 090572-10-8 (CUSIP Number) Alice N. Schwartz 1000 Alfred Nobel Drive Hercules, California 94547 (510) 741-6000 (Name, Add |
|
| March 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. |
|
| March 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: March 23, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| March 2, 2022 |
Exhibit 4.1 Bio-Rad Laboratories, Inc. INDENTURE Dated as of March 2, 2022 Wilmington Trust, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section |
|
| March 2, 2022 |
Form of Global Security for the 3.300% Senior Notes due 2027. (6) Exhibit 4.3 BIO-RAD LABORATORIES, INC. THIS GLOBAL NOTE IS HELD BY THE DEPOSITARY (AS DEFINED IN THE FIRST SUPPLEMENTAL INDENTURE GOVERNING THIS NOTE) OR ITS NOMINEE IN CUSTODY FOR THE BENEFIT OF THE BENEFICIAL OWNERS HEREOF, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT THAT (I) THE TRUSTEE MAY MAKE SUCH NOTATIONS HEREON AS MAY BE REQUIRED PURSUANT TO SECTION 3.02 OF THE FI |
|
| March 2, 2022 |
Exhibit 1.1 Bio-Rad Laboratories, Inc. $400,000,000 3.300% Senior Notes due 2027 $800,000,000 3.700% Senior Notes due 2032 UNDERWRITING AGREEMENT February 23, 2022 Citigroup Global Markets Inc. 388 Greenwich Street New York, New York 10013 Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 As Representatives of th |
|
| March 2, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 23, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact Name of Registrant as Specified in its Charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| March 2, 2022 |
Exhibit 4.2 BIO-RAD LABORATORIES, INC. as Issuer and WILMINGTON TRUST, NATIONAL ASSOCIATION as Trustee FIRST SUPPLEMENTAL INDENTURE Dated as of March 2, 2022 to the Indenture dated as of March 2, 2022 3.300% Senior Notes due 2027 3.700% Senior Notes due 2032 TABLE OF CONTENTS Page ARTICLE 1 APPLICATION OF FIRST SUPPLEMENTAL INDENTURE Section 1.01. Application of First Supplemental Indenture 1 ARTI |
|
| March 2, 2022 |
Announces Closing of $1.2 Billion Aggregate Senior Notes Offering Exhibit 99.1 Bio-Rad Announces Closing of $1.2 Billion Aggregate Senior Notes Offering HERCULES, California?March 2, 2022?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today the closing of its underwritten public offering of $1.2 billion aggregate principal amount of the following notes (the ?Notes?), each issu |
|
| March 2, 2022 |
Form of Global Security for the 3.700% Senior Notes due 2032. (7) Exhibit 4.4 BIO-RAD LABORATORIES, INC. THIS GLOBAL NOTE IS HELD BY THE DEPOSITARY (AS DEFINED IN THE FIRST SUPPLEMENTAL INDENTURE GOVERNING THIS NOTE) OR ITS NOMINEE IN CUSTODY FOR THE BENEFIT OF THE BENEFICIAL OWNERS HEREOF, AND IS NOT TRANSFERABLE TO ANY PERSON UNDER ANY CIRCUMSTANCES EXCEPT THAT (I) THE TRUSTEE MAY MAKE SUCH NOTATIONS HEREON AS MAY BE REQUIRED PURSUANT TO SECTION 3.02 OF THE FI |
|
| February 25, 2022 |
Exhibit 107 Calculation of Filing Fee Tables 424(b)(2) (Form Type) BIO-RAD LABORATORIES, INC. |
|
| February 25, 2022 |
$1,200,000,000 $400,000,000 3.300% Senior Notes due 2027 $800,000,000 3.700% Senior Notes due 2032 Table of Contents Filed Pursuant to Rule 424(b)(2) Registration No. 333-262737 PROSPECTUS SUPPLEMENT (To Prospectus dated February 15, 2022) $1,200,000,000 $400,000,000 3.300% Senior Notes due 2027 $800,000,000 3.700% Senior Notes due 2032 We are offering $400,000,000 aggregate principal amount of our 3.300% Senior Notes due 2027 (the ?2027 notes?), and $800,000,000 aggregate principal amount of o |
|
| February 25, 2022 |
Exhibit 99.1 F E B R U A R Y 2 5 , 2 0 2 2 Bio-Rad Investor Laboratories, Inc. Day 2022 Forward-Looking Statements & Use of Non-GAAP Reporting Forward-looking Statements. Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management?s goals, plans, and |
|
| February 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 25, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 25, 2022 |
Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day Exhibit 99.2 Press Release Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day HERCULES, Calif.?February 25, 2022? Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginning at 10:30 a.m. EST today in New York City. During the event, members of Bio-Rad? |
|
| February 24, 2022 |
FWP 1 d84576dfwp.htm FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration No. 333-262737 Relating to the Preliminary Prospectus Supplement dated February 23, 2022 Bio-Rad Laboratories, Inc. Pricing Term Sheet February 23, 2022 $400,000,000 3.300% Senior Notes due 2027 $800,000,000 3.700% Senior Notes due 2032 Issuer: Bio-Rad Laboratories, Inc. (the “Company”) Trade Date: Febr |
|
| February 23, 2022 |
SUBJECT TO COMPLETION, DATED FEBRUARY 23, 2022 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-262737 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission under the Securities Act of 1933. This preliminary prospec |
|
| February 15, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) BIO-RAD LABORATORIES, INC. |
|
| February 15, 2022 |
As filed with the Securities and Exchange Commission on February 15, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 15, 2022 Registration No. |
|
| February 15, 2022 |
Exhibit 4.2 Bio-Rad Laboratories, Inc. INDENTURE Dated as of , Wilmington Trust, National Association Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 5 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuabl |
|
| February 15, 2022 |
Statement of Eligibility of trustee under the Indenture. Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 ? Check if an Application to Determine Eligibility of a Trustee Pursuant to Section 305(b)(2) WILMINGTON TRUST, NATIONAL ASSOCIATION (Exact name of trustee as specified in its charter) 16-1486454 (I.R.S. employer identification no.) 1100 North Market Street Wilmington, DE 19890-0001 (Address of principal |
|
| February 11, 2022 |
Executive Change in Control Severance Plan Adopted 2-10-2022 EXHIBIT 10.9 BIO-RAD LABORATORIES, INC. EXECUTIVE CHANGE IN CONTROL SEVERANCE PLAN The purpose of the Bio-Rad Laboratories, Inc. Executive Change in Control Severance Plan (as amended and in effect from time to time, the ?Plan?), is to provide key executives with certain severance benefits upon their termination of employment following a Change in Control. The Compensation Commit |
|
| February 11, 2022 |
Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria DiaMed ?sterreich GmbH Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium DiaMed Benelux NV Belgium Bio-Rad Laborat?rios Brasil Ltda. Brazil DiaMed Latino-Am?rica S.A. Brazil Bio-Rad Laboratories (Rishon), |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORIES, INC |
|
| February 10, 2022 |
Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2021 Financial Results HERCULES, Calif.?February 10, 2022?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and year ended December 31, 2021. Fourth-quarter 2021 net sales were $732.8 million, a de |
|
| February 10, 2022 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 10, 2022 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 9, 2022 |
BIO / Bio-Rad Laboratories, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 1 BIO-RAD LABORATORIES INC CLASS A COMMON STOCK Cusip #090572207 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #090572207 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 269,416 Item 6: 0 Item 7: 1,928,323 Item 8: 0 Item 9: 1,928,323 |
|
| February 9, 2022 |
BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Bio-Rad Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 1, 2022 |
BIO / Bio-Rad Laboratories, Inc. / BlackRock Inc. Passive Investment us0905722072013122.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) BIO RAD LABORATORIES INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 090572207 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| November 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 21, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| November 18, 2021 |
Exhibit 10.1 EXECUTION COPY AMENDMENT NO. 1 Dated as of November 15, 2021 to CREDIT AGREEMENT Dated as of April 15, 2019 THIS AMENDMENT NO. 1 (this ?Amendment?) is made as of November 15, 2021 by and among Bio-Rad Laboratories, Inc. (the ?Borrower?), the financial institutions listed on the signature pages hereof and JPMorgan Chase Bank, N.A., as Administrative Agent (the ?Administrative Agent?), |
|
| November 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 15, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| October 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA |
|
| October 28, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 28, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| October 28, 2021 |
Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2021 Financial Results HERCULES, Calif.?October 28, 2021?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2021. Third-quarter 2021 net sales were $747.0 million, an increase of 15.4 percent co |
|
| October 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: September 28, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| July 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORAT |
|
| July 29, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 29, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco |
|
| July 29, 2021 |
Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2021 Financial Results HERCULES, Calif.?July 29, 2021?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2021. Second-quarter 2021 net sales were $715.9 million, an increase of 33.4 percent compare |
|
| May 17, 2021 |
Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (?Bio-Rad? or the ?Company?) is for calendar year 2020 in accordance with Rule 13p-1 (?Rule 13p-1?) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (?SEC?) adopted Rule 13-p-1 to implement reporting and disclosure requirements relating to co |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 1-7928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal Ex |
|
| April 30, 2021 |
Quarterly Report - 10-Q MARCH 31, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORA |
|
| April 29, 2021 |
Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2021 Financial Results HERCULES, Calif.?April 29, 2021?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2021. First-quarter 2021 net sales were $726.8 million, an increase of 27.1 percent compared |
|
| April 29, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 29, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) Definitive Prox |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORIES, INC |
|
| February 16, 2021 |
Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria DiaMed ?sterreich GmbH Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium DiaMed Benelux NV Belgium Bio-Rad Laborat?rios Brasil Ltda. Brazil DiaMed Latino-Am?rica S.A. Brazil Bio-Rad Laboratories (Rishon), |
|
| February 11, 2021 |
Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2020 Financial Results HERCULES, Calif.–February 11, 2021–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter ended December 31, 2020. Fourth-quarter 2020 net sales were $789.8 million, an increase o |
|
| February 11, 2021 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 11, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Bio-Rad Laboratories Inc. Class A Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 8, 2021 |
SCHEDULE 13G Amendment No. 0 BIO-RAD LABORATORIES INC CLASS A COMMON STOCK Cusip #090572207 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #090572207 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 270,714 Item 6: 0 Item 7: 1,692,254 Item 8: 0 Item 9: 1,692,254 |
|
| February 4, 2021 |
Costs Associated with Exit or Disposal Activities - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 3, 2021 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| January 29, 2021 |
us0905722072012821.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) BIO RAD LABORATORIES INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 090572207 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| January 22, 2021 |
United States securities and exchange commission logo January 22, 2021 Ilan Daskal Chief Financial Officer BIO-RAD LABORATORIES, INC. |
|
| January 22, 2021 |
United States securities and exchange commission logo January 22, 2021 Ilan Daskal Chief Financial Officer BIO-RAD LABORATORIES, INC. |
|
| January 5, 2021 |
Bio-Rad Laboratories, Inc. Corporate Offices 1000 Alfred Nobel Drive Hercules, California 94547 Phone: 510-724-7000 Fax: 510-741-4048 January 5, 2021 Jeanne Bennett Division of Corporation Finance Office of Life Sciences U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549 Subject: Bio-Rad Laboratories, Inc. Form 10-K for the Year Ended December 31, 2019 Filed March 2, 202 |
|
| December 29, 2020 |
United States securities and exchange commission logo December 29, 2020 Ilan Daskal Chief Financial Officer BIO-RAD LABORATORIES, INC. |
|
| December 29, 2020 |
United States securities and exchange commission logo December 29, 2020 Ilan Daskal Chief Financial Officer BIO-RAD LABORATORIES, INC. |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 10, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| December 10, 2020 |
Exhibit 99.2 Press Release Bio-Rad Provides Outlook Through 2023 HERCULES, Calif ?December 10, 2020?Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today its outlook through 2023, which shows the company?s commitment to continued organic growth, continued margin expansion, and its efforts on sustainability measur |
|
| December 10, 2020 |
Exhibit 99.1 OUTLOOK: 2021 ? 2023 Bio-Rad Laboratories, Inc. December 10, 2020 ? 2020 Bio-Rad Laboratories, Inc. All rights reserved.Exhibit 99.1 OUTLOOK: 2021 ? 2023 Bio-Rad Laboratories, Inc. December 10, 2020 ? 2020 Bio-Rad Laboratories, Inc. All rights reserved. FORWARD-LOOKING STATEMENTS & USE OF NON-GAAP REPORTING Forward-looking Statements. Some statements in this presentation may be forwar |
|
| October 30, 2020 |
BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN GLOBAL RESTRICTED STOCK Unit AWARD GRANT NOTICE Bio-Rad Laboratories, Inc., a Delaware corporation, (the “Company”), pursuant to its 2017 Incentive Award Plan, as amended from time to time (the “Plan”), hereby grants to the individual listed below (“Holder”), Restricted Stock Units (“RSUs”) with respect to the number of shares of the Company’s C |
|
| October 30, 2020 |
Quarterly Report - 10-Q SEPTEMBER 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA |
|
| October 30, 2020 |
BIO-RAD LABORATORIES, INC. 2017 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE AND NON-QUALIFIED STOCK OPTION AGREEMENT (United States HOLDERS) Bio-Rad Laboratories, Inc., a Delaware corporation (the “Company”), pursuant to its 2017 Incentive Award Plan (the “Plan”), hereby grants to the holder listed below (“Holder”), an option to purchase the number of shares of the Company’s Class A common stoc |
|
| October 29, 2020 |
Results of Operations and Financial Condition - 8-K 10.29.20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 29, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| October 29, 2020 |
Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2020 Financial Results HERCULES, Calif.–October 29, 2020–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2020. Third-quarter 2020 net sales were $647.3 million, an increase of 15.5 percent co |
|
| September 4, 2020 |
POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of Ronald W. |
|
| July 31, 2020 |
Quarterly Report - 10-Q JUNE 30, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORAT |
|
| July 30, 2020 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: July 30, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco |
|
| July 30, 2020 |
Exhibit 99.1 Press Release Bio-Rad Reports Second-Quarter 2020 Financial Results HERCULES, Calif.–July 30, 2020–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2020. Second-quarter 2020 net sales were $536.9 million, a decrease of 6.2 percent compared |
|
| May 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form SD SPECIALIZED DISCLOSURE REPORT Bio-Rad Laboratories, Inc. (Exact Name of Registrant as Specified in Charter) DELAWARE 1-7928 94-1381833 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification Number) 1000 Alfred Nobel Drive, Hercules, California 94547 (Address of Principal Ex |
|
| May 28, 2020 |
Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Bio-Rad Laboratories, Inc. Conflict Minerals Report This Conflict Minerals Report of Bio-Rad Laboratories, Inc. (“Bio-Rad” or the “Company”) is for calendar year 2019 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934. The Securities and Exchange Commission (“SEC”) adopted Rule 13-p-1 to implement reporting and disclosure requirements relating to co |
|
| May 21, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 21, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incor |
|
| May 8, 2020 |
Quarterly Report - 10-Q MARCH 31, 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LABORA |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: May 6, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of incorp |
|
| May 6, 2020 |
Exhibit 99.1 Press Release Bio-Rad Reports First-Quarter 2020 Financial Results HERCULES, Calif.-May 6, 2020-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2020. First-quarter 2020 net sales were $571.6 million, an increase of 3.2 percent compared to |
|
| May 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 28, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inc |
|
| April 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: April 1, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of inco |
|
| April 1, 2020 |
BIO / Bio-Rad Laboratories, Inc. DEF 14A - - BIO RAD LABORATORIES INC - DEF 14A BIO-RAD LABORATORIES, INC. - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for use of the Commission only (as permitted |
|
| March 2, 2020 |
Exhibit 21.1 LISTING OF SUBSIDIARIES JURISDICTION OF SUBSIDIARY ORGANIZATION Bio-Rad Laboratories Pty Ltd Australia Bio-Rad Laboratories Ges.m.b.H. Austria DiaMed Österreich GmbH Austria Bio-Rad Laboratories NV Belgium Research Specialties for Laboratories NV Belgium DiaMed Benelux NV Belgium Bio-Rad Laboratórios Brasil Ltda. Brazil DiaMed Latino-América S.A. Brazil Bio-Rad Laboratories (Rishon), |
|
| March 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-7928 BIO-RAD LABORATORIES, INC |
|
| March 2, 2020 |
Description of Bio-Rad Laboratories, Inc. Class A and Class B Common Stock Exhibit 4.1 DESCRIPTION OF BIO-RAD LABORATORIES, INC. CLASS A AND CLASS B COMMON STOCK The following description of Bio-Rad Laboratories, Inc.’s (“Bio-Rad’s”) Class A Common Stock and Class B Common Stock is a summary. This summary is subject to the General Corporation Law of the State of Delaware (the “DGCL”), the complete text of Bio-Rad’s Restated Certificate of Incorporation and Certificate of |
|
| March 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 25, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 13, 2020 |
Exhibit 99.1 Press Release Bio-Rad Reports Fourth-Quarter and Full-Year 2019 Financial Results HERCULES, Calif.- February 13, 2020-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2019. Fourth-quarter 2019 net sales were $624.4 million |
|
| February 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: February 13, 2020 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| February 12, 2020 |
BIO / Bio-Rad Laboratories, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Bio-Rad Laboratories Inc Title of Class of Securities: Common Stock CUSIP Number: 090572207 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| February 5, 2020 |
BIO / Bio-Rad Laboratories, Inc. / BlackRock Inc. Passive Investment us0905722072020420.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 6) BIO RAD LABORATORIES INC - (Name of Issuer) Class A Common Stock - (Title of Class of Securities) 090572207 - (CUSIP Number) December 31, 2019 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| December 9, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: December 5, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| November 25, 2019 |
Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: November 21, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of |
|
| November 1, 2019 |
Quarterly Report - 10-Q SEPTEMBER 30, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromto Commission file number 1-7928 BIO-RAD LA |
|
| October 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: October 31, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of i |
|
| October 31, 2019 |
Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2019 Financial Results HERCULES, Calif.-October 31, 2019-Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2019. Third-quarter 2019 net sales were $560.6 million, an increase of 2.8 percent com |
|
| August 27, 2019 |
EX-99.1 Exhibit 99.1 Corrected Press Release Bio-Rad Reports Second-Quarter 2019 Financial Results HERCULES, Calif.–August 27, 2019– This press release corrects a prior version published on August 1, 2019. The prior press release contained a $3.37 million error with respect to Legal Matters used in the non-GAAP financial presentation. This corrected press release does not change the GAAP results o |
|
| August 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 1, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other |
|
| August 23, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report: August 20, 2019 (Date of earliest event reported) BIO-RAD LABORATORIES, INC. (Exact name of registrant as specified in its charter) Commission File Number: 1-7928 Delaware 94-1381833 (State or other jurisdiction of in |
|
| August 23, 2019 |
Retirement Agreement between the Company and John Hertia made as of August 21, 2019 EX-10.1 Exhibit 10.1 Retirement Agreement THIS RETIREMENT AGREEMENT (the “Agreement”) is made as of this 21st day of August 2019, by and between BIO-RAD LABORATORIES, INC. (“Company”) and John Hertia (“Executive”) (individually, a “PARTY”, and collectively, the “PARTIES”). It shall outline the agreed upon terms for Executive’s retirement from company as follows: 1. Retirement Date. The parties agr |
